Related Experiment Video
Updated: May 14, 2026
Coculture System with an Organotypic Brain Slice and 3D Spheroid of Carcinoma Cells
Published on: October 9, 2013
Metastatic carcinoid tumors--are we making the cut?
Kathryn E Coan1, Richard J Gray, Richard T Schlinkert
1Department of Surgery, Mayo Clinic, Phoenix, AZ 85054, USA.
Background:
Although controversial, surgical resection for metastatic carcinoid tumors (MCTs) can potentially prolong survival.
Methods:
Patients with MCTs were identified from the Surveillance, Epidemiology and End Results database. Patients undergoing surgery were compared to unresected patients.
Results:
Surgery was performed in 33% of patients. Predictors of surgery included age <50 years (odds ratio [OR], 2.4), low grade (OR, 3.1), and the appendix (OR, 36.2) or small intestine (OR, 27.2) as the primary site. Predictors of adverse survival included high grade (hazard ratio, 2.4) and no surgery (hazard ratio, 2.5) or surgery on only primary or distant disease (hazard ratio, 1.5) compared with surgery for both. Survival at 5 years was 5% with no surgery, 28% with surgery on either site, and 46% with surgery at both sites (P < .001).
Conclusions:
Surgery for MCTs is more common in younger patients, those with low-grade disease, and those with small bowel or appendiceal primary tumors. Although selection bias cannot be excluded, these data lend support to "debulking" for MCT.
